Arcutis Biotherapeutics Inc

Arcutis CFO sells 435 shares amid a 10% stock drop; insider selling signals cautious confidence and may signal future restructuring.

Arcutis insider Matsuda Masaru sells 7,372 shares at $23.27, a routine sale amid 2026 liquidity plans; investors note the move’s minimal impact on a 78 % YTD rally and upcoming clinical milestones.

Arcutis Biotherapeutics insider sales show routine tax‑planning, not declining confidence—insiders keep a strong stake while the company’s immune‑disease pipeline drives future growth.

Arcutis insider selling trends: Howard’s 77k-share exit plan and its impact on the stock’s 71% Y/Y rise, valuation, and future buying opportunities.

Leonard Keith R’s recent buy‑heavy trades at Arcutis signal confidence in its clinical pipeline, offering insight for long‑term investors navigating the stock’s volatility.

Arcutis insider buying shows executive confidence amid volatility—insight on Patrick’s 30% stake growth and market‑sensitive dynamics.

Arcutis insider buys reveal long‑term confidence: Todd’s $0 RSU purchase and steady holdings suggest a bullish future despite short‑term price dips.

Arcutis insider selling is a planned, rule‑based strategy—investors should focus on the company’s positive biotech pipeline and market sentiment to gauge future upside.

Arcutis insider selling: Patrick’s tax‑plan sale is routine, not a red flag, amid strong market momentum and ZORYVE gains.

Arcutis Biotherapeutics insider sale: CMO Burnett Patrick sells 2,490 shares under a 10b‑5‑1 plan, hinting at short‑term liquidity amid volatile stock and uncertain earnings.